secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001193125-23-128896
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports $159.5M cash as of March 31, 2023; runway into Q4 2024
----------------------------------------------------------------------

- Cash and marketable securities totaled $159.5M as of March 31, 2023 (preliminary, unaudited).
- Company confirms cash runway extends into at least the fourth quarter of 2024.
- Preliminary estimate subject to change; actual results may differ materially.
- Update provided in connection with virtual investor event on May 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/0001193125-23-128896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523128896/d505148d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-128896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer